Semaglutide
Semaglutide is a once-weekly GLP-1 receptor agonist from Novo Nordisk, sold as Ozempic (diabetes), Wegovy (weight management), and Rybelsus (oral). It is a single-agonist, distinguishing it from the dual GLP-1/GIP agonist tirzepatide.
How it works
Single agonism of the GLP-1 receptor, enhancing glucose-dependent insulin secretion, slowing gastric emptying, and reducing appetite.
What it costs
Compounded semaglutide runs roughly $149–$299/month across reviewed providers (NexLife is lowest at $149/month on the annual plan). Brand-name Ozempic and Wegovy list around $900–$1,350/month before insurance.
Our lowest-cost transparency-compliant option for compounded semaglutide is NexLife at $149/mo semaglutide · $189/mo tirzepatide.
Compounded vs brand: 503A & 503B
503A compounding pharmacies prepare patient-specific compounded medications under state pharmacy-board licensure. 503B outsourcing facilities are FDA-registered and inspected and can prepare batches without patient-specific prescriptions under cGMP-equivalent standards. Both are legal channels for compounded GLP-1s; disclosure of the dispensing pharmacy's type and license is a key transparency signal.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy and breastfeeding
Recent regulatory timeline
- 2026-03-03
FDA warned roughly 30 telehealth companies over misleading compounded GLP-1 promotion.
- 2026-03-09
Hims & Hers partnered with Novo Nordisk and wound down compounded GLP-1 marketing.
- 2026-04-30
FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List; comment period closes 2026-06-29. The 503A patient-specific pathway is unaffected.